Remedi4All Events « All Events

On February 6, C-Path is going to host a 90-minute roundtable discussing the Critical Path Institute’s programs and consortia, highlighted by various women leaders at this public-private partnership. The team...

Health literacy, patient empowerment, shared decision-making and patient involvement are no buzzwords, but major cornerstones of a successful, efficient and effective patient-centred healthcare. All patients have the right to receive...

The 4th Value Added Medicines Conference - #VAM22 - takes place on 30 November 2022 in Brussels (Belgium). The theme this year is "Giving medicines a new life". Value Added...

The workshop “Broad-spectrum anti-viral therapeutics: A key tool for pandemic preparedness" is going to take place on 22 and 23 November 2022 in Brussels, Belgium. The workshop will be focusing...

The World Orphan Drug Congress is an award-winning event with an exhibition that has grown to become the largest and most established orphan drugs & rare diseases meeting of its kind across the globe.

Learn about the latest technologies, partnerships and advances propelling the field of repurposing and re-shaping drug discovery and development.

KI NMA is proud to invite you to participate in an advanced course in Network medicine - “From byte to bench to bed side – addressing large and complex data...

Our annual conference, Drug Repurposing for Rare Diseases, highlights the role that drug repurposing can play in lowering the cost and accelerating the development of rare disease treatments.

This years CeBIL symposium will focus on important policy issues for pharmaceutical repurposing. In particular, it will examine new empirical data on patent protection, regulatory exclusivities and market authorisation pathways.

RExPO22 is the first installment in the RExPO conference series. The conference will take place in Maastricht, The Netherlands, from September 2nd to 3rd, 2022 and we are already looking forward to share the occasion with such a vibrant community of researchers and innovators.